Joanne L. Blum, MD, PhD

Articles by Joanne L. Blum, MD, PhD

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

ByGabrielle Rocque,Joanne L. Blum, MD, PhD,Yan Ji,Eric Gauthier,Yao Wang,Monica Z. Montelongo,Joseph C. Cappelleri,Connie Chen,Meghan S. Karuturi,Debu Tripathy, MD

July 24th 2024

35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

ByDebu Tripathy, MD,Joanne L. Blum, MD, PhD,Meghan S. Karuturi,Monica Z. Montelongo,Zhe Zhang,Eric Gauthier,Gabrielle Rocque

June 25th 2024

Update on the Management of Advanced Breast Cancer

ByJoanne L. Blum, MD, PhD

May 1st 1999

Fornier et al present an excellent summary of current treatment options and strategies for patients with metastatic breast cancer. This review summarizes currently available data (through the May 1998 American Society of Clinical Oncology

Latest Updated Articles

Update on the Management of Advanced Breast Cancer
May 1st 1999

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)